Profitability
Weight: 25%
D-
30
- 5yr Avg ROIC -18.7%
- Operating Margin Trend +101.36 pp/yr
TBPH
Theravance Biopharma, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 3 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
A+
100
- 5yr Avg ROE 45.0%
- 5yr Share-Count CAGR -7.2%
Growth Quality
Weight: 25%
B-
62
- 5yr Revenue CAGR 18.1%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
C-
45
- 5yr FCF Margin -119.0%
- 5yr FCF/NI Conversion 1.02x
Balance Sheet
Weight: 10%
F
7
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -5.38x
- Altman Z-Score 1.46
Stability
Weight: 5%
A-
83
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 7
- Negative-Revenue Years (5) 2/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 3 gurus held; 1 added; 1 trimmed; 1 full exit.
- Holders
- 2 -1
- Avg Δ position
- +37.5%
- New buys
- 0
- Full exits
- 1
- Wood sold -100%
- Greenblatt increased +99%
- Cooperman decreased -24%